Ravgen, Inc. v. Laboratory Corporation of America Holdings

CourtDistrict Court, W.D. Texas
DecidedJanuary 28, 2022
Docket6:20-cv-00969
StatusUnknown

This text of Ravgen, Inc. v. Laboratory Corporation of America Holdings (Ravgen, Inc. v. Laboratory Corporation of America Holdings) is published on Counsel Stack Legal Research, covering District Court, W.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ravgen, Inc. v. Laboratory Corporation of America Holdings, (W.D. Tex. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS WACO DIVISION

RAVGEN, INC., § Plaintiff § § W-20-CV-00969-ADA -vs- § § LABORATORY CORPORATION OF § AMERICA HOLDINGS, § Defendant §

MEMORANDUM OPINION AND ORDER Before the Court is Defendant Laboratory Corporation of America Holdings’ (“LabCorp”) Opposed Motion for Leave of Court to File Motion to Transfer Venue Under 28 U.S.C. § 1404(a) (the “Motion”). ECF No. 72. After review of the relevant briefing, including Plaintiff Ravgen, Inc.’s (“Ravgen”) Response (ECF No. 77) and LabCorp’s Reply (ECF No. 78), the Court DENIES LabCorp’s Motion. I. BACKGROUND Ravgen filed suit against LabCorp in October of 2020. ECF No. 1. On January 11, 2021, Defendant filed its Answer and asserted certain counterclaims against Ravgen. ECF No. 19. On January 18, 2021, Ravgen filed the Case Readiness Status Report, indicating no motions were pending and that three other related cases were in this district.1 In May of 2021, the parties filed a joint proposed scheduling order, and on September 20, 2021, the Court held the Markman for the instant case and its companion case, Ravgen, Inc. v. Quest Diagnostics Inc., 6:20-cv-00972- ADA. The Court issued its written claim construction order (ECF No. 62), and the parties are in the midst of fact discovery. ECF No. 77 at 1. Months after the Markman hearing, on November

1 Ravgen, Inc. v. PerkinElemer Inc. et al., 1:20-cv-00822-ADA; Ravgen, Inc. v. Natera, Inc. et al., 1:20-cv-00692- ADA; and Ravgen, Inc. v. Quest Diagnostics Inc., 6:20-cv-00972-ADA. 23, 2021, Defendant LabCorp filed this Motion, seeking leave to file a motion to transfer venue under 28 U.S.C. § 1404(a). ECF No. 72. Trial is scheduled for September of this year. The Motion has been fully briefed and is ripe for review.

II. LEGAL STANDARD Motions to transfer patent cases are governed by regional circuit law. In re TS Tech USA Corp., 551 F.3d 1315, 1319 (Fed. Cir. 2008). A party seeking transfer “should not delay filing” and must act with “reasonable promptness.” In re Wyeth, 406 F. App’x 475, 477 (Fed. Cir. 2010); Peteet v. Dow Chem. Co., 868 F.2d 1428, 1436 (5th Cir. 1989). Otherwise, “the court [will] expend time and effort that might become wasted upon transfer.” In re Wyeth, 406 F. App’x at 477.

A transfer motion filed after a court deadline should only be allowed if the motion is timely and shows good cause for the delay. O’Connor v. Smith, No. CIV.A. C-10-77, 2010 WL 4366914, at *1 n.1 (S.D. Tex. Oct. 28, 2010) (denying transfer motion “as moot because it is untimely and not filed with good cause”); see also, e.g., Charter Sch. Sols. v. GuideOne Mut. Ins. Co., 333 F.R.D. 97, 102 (W.D. Tex. 2019) (denying amendment to court deadlines because movant “has not shown its inability to meet the Court’s deadlines despite any diligence, and all four factors weigh against good cause”). Good cause requires “the party seeking relief to show that the deadlines cannot reasonably be met despite the diligence of the party needing the extension.” Sw. Bell Tel. Co. v.

City of El Paso, 315 F.3d 533, 535 (5th Cir. 2003) (quoting 6A Charles Alan Wright et al., FEDERAL PRACTICE AND PROCEDURE § 1522.1 (2d ed. 1990)) (internal quotation marks omitted). Courts consider four factors in determining good cause: “(1) the explanation for the failure to timely move for leave to amend; (2) the importance of the amendment; (3) potential prejudice in allowing the amendment; and (4) the availability of a continuance to cure such prejudice.” Sw. Bell Tel. Co. v. City of El Paso, 346 F.3d 541, 546 (5th Cir. 2003).

III. ANALYSIS A. Motion for Leave Defendant LabCorp argues that good cause exists to file its Motion to Transfer “as circumstances of the instant litigation have recently changed, making the Southern District of California clearly a more convenient forum.” ECF No. 72 at 1. In support of its argument, LabCorp relies on two propositions: (1) the Federal Circuit allegedly provided a “sharp change of law” that is now grounds for transfer, and (2) no related co-pending cases remain before the

Court. Id. at 1–2. Of the related cases previously mentioned, LabCorp highlights that one was dismissed, one was transferred to the Central District of California, and one was transferred to another judge within the Western District of Texas. Id. LabCorp therefore believes that the convenience factors now tip in favor of transfer. Ravgen plainly disagrees and asks that this Court deny LabCorp’s Motion because it is untimely, would result in a waste of resources, and lacks good cause. Ravgen emphasizes that LabCorp waited thirteen months to seek transfer and fails to provide any credible explanation for its delay. Such delay, Ravgen argues, presents indisputable prejudice that cannot be cured. 1. LabCorp’s transfer motion is not timely. LabCorp and Ravgen dispute the timeliness of LabCorp’s transfer motion. The central

issue is whether the Motion’s timeliness is predicated on the date of the Court’s standing order, or the date of the alleged change in law and transfer of the last co-pending case. Parties are free to file transfer motions without leave until eight weeks before Markman hearings. See Second Amended Standing Order Regarding Motion for Inter-District Transfer [for Patent Cases], (W.D. Tex. Aug. 18, 2021). LabCorp did not meet that deadline—the motion, absent good cause, is not timely. The Court’s standing order reflects Fifth Circuit law, which requires that parties “not delay [the] filing of a motion to transfer” and that transfer to be sought with “reasonable promptness.” In re Wyeth, 406 F. App’x 475, 477 (Fed. Cir. 2010); Peteet v. Dow Chem. Co.,

868 F.2d 1428, 1436 (5th Cir. 1989). As our sister courts have stated, “late-filed motions to transfer are looked upon with extreme disfavor.” ATEN Int’l Co. v. Emine Tech. Co., 261 F.R.D. 112, 126 n.4 (E.D. Tex. 2009). LabCorp’s timeliness argument is particularly null given the weakness of its foundational propositions—that a change in law and disposition of co-pending cases triggers the Motion’s timeliness. 2. LabCorp lacks good cause. “LabCorp’s position is that the Federal Circuit clarified and provided further guidance as to the weight and specificity of the factors pertinent to transfer motions.” ECF No. 78 at 2. LabCorp cites to three orders of this Court wherein the Court amended prior orders. Specifically, LabCorp argues that the Federal Circuit changed the calculus in favor of transfer to the Southern

District of California with respect to the sources of proof, compulsory process, convenience of the witnesses, practical problems, court congestion, and local interest factors. Ravgen contends that none of the Federal Circuit opinions identified a law change, nor were any precedential. Similarly, Ravgen argues there has been no change in the facts. For example, “the disposition of Ravgen’s related cases does not reduce the judicial economies of retaining this case before this Court.” Ravgen further argues that LabCorp fails to show the importance of transfer, and even alleges LabCorp identified certain witness employees solely for the purpose of its transfer motion. ECF No. 77 at 8.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Ravgen, Inc. v. Laboratory Corporation of America Holdings, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ravgen-inc-v-laboratory-corporation-of-america-holdings-txwd-2022.